KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Treasury Shares (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Treasury Shares for 13 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 81.97% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 81.97%, while the annual FY2025 figure was $1.7 million, 81.97% up from the prior year.
  • Treasury Shares hit $1.7 million in Q4 2025 for Alnylam Pharmaceuticals, up from $954000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.7 million in Q4 2025 and bottomed at $292000.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.0 million, with a median of $1.0 million recorded in 2023.
  • Year-over-year, Treasury Shares tumbled 74.3% in 2022 and then surged 251.03% in 2023.
  • Alnylam Pharmaceuticals' Treasury Shares stood at $1.1 million in 2021, then crashed by 74.3% to $292000.0 in 2022, then soared by 251.03% to $1.0 million in 2023, then fell by 6.93% to $954000.0 in 2024, then skyrocketed by 81.97% to $1.7 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $1.7 million, $954000.0, and $1.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.